jetcityimage/iStock Editorial via Getty Images A U.K. watchdog has declined to endorse Eli Lilly’s ( NYSE: LLY ) Alzheimer’s drug donanemab for use in the country's national health service (NHS), noting that therapy was too costly to warrant coverage in Britain.
The National Institute for Health and Care.
